Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects-Reference-Cited by-同舟云学术

Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects

Published:2010-10 Issue:45 Volume:28 Page:7306-7312
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Howles Sarah,Guimarães-Walker Ana,Yang Hongbing,Hancock Gemma,di Gleria Katalin,Tarragona-Fiol Tony,Hayes Peter,Gilmour Jill,Bridgeman Anne,Hanke Tomáš,McMichael Andrew,Dorrell Lucy

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference28 articles.

1. HIV vaccines: new frontiers in vaccine development;Duerr;Clin Infect Dis,2006

2. HIV vaccines;McMichael;Annu Rev Immunol,2006

3. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysis;McElrath;Lancet,2008

4. Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines;Tatsis;Blood,2007

5. Biodistribution and persistence of an MVA-vectored candidate HIV vaccine in SIV-infected rhesus macaques and SCID mice;Hanke;Vaccine,2005

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment of CD8+ T-cell mediated immunity in an influenza A(H3N2) human challenge model in Belgium: a single centre, randomised, double-blind phase 2 study;The Lancet Microbe;2024-07

2. Efficacy and safety of a universal influenza A vaccine (MVA-NP+M1) in adults when given after seasonal quadrivalent influenza vaccine immunisation (FLU009): a phase 2b, randomised, double-blind trial;The Lancet Infectious Diseases;2022-06

3. Efficacy and Safety of a Modified Vaccinia Ankara-NP+M1 Vaccine Combined with QIV in People Aged 65 and Older: A Randomised Controlled Clinical Trial (INVICTUS);Vaccines;2021-08-03

4. An Overview of Nanocarrier-Based Adjuvants for Vaccine Delivery;Pharmaceutics;2021-03-27

5. Comparison of Safety and Vector-Specific Immune Responses in Healthy and HIV-Infected Populations Vaccinated with MVA-B;Vaccines;2019-11-07